A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
Chen, M.Y. and Luo, L.P. (2026) CT and MRI Findings of Epithelioid Hemangioma of Bone: A Case Report. Journal of Biosciences and Medicines, 14, 246-252. doi: 10.4236/jbm.2026.143018 .
US FDA accepts and grants priority review status to AstraZeneca and Daiichi Sankyo’s sBLA for Enhertu to treat adult patients with HER2-positive early breast cancer: Cambridge, ...
A new research paper was published in Volume 13 of Oncoscience on February 7, 2026, titled “Reduced immunogenicity of MYC amplified, metastatic prostate cancer.” ...
Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains ...
Daiichi Sankyo submits Enhertu sNDA in Japan as adjuvant therapy for patients with HER2 positive early breast cancer: Tokyo Monday, March 2, 2026, 12:00 Hrs [IST] Daiichi Sankyo h ...
MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics ...
A new ultra-high-throughput sequencing platform boosts output, speeds turnaround, and improves genome coverage. It reduces costs, broadens clinical applications, and accelerates large-scale genomics ...
Using a CRISPR-based biosensor platform, researchers have detected microRNA biomarkers of Alzheimer’s disease, with the ...
The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results